MaxCyte CEO Says FDA OK Of IND For Its CAR Receptor Candidate Major Milestone

 
• By Sten Stovall

MaxCyte's first next-generation chimeric antigen receptor MCY-M11 will be studied in solid tumors.

CART
IND Means First CARMA Trial Is On Track For Dosing In Second Half 2018 • Source: Shutterstock

More from Clinical Trials

More from R&D